

January 8, 2026

The Honorable Morgan Griffith
Chairman, Subcommittee on Health
Committee on Energy and Commerce
U.S. House of Representatives
Washington, DC 20515

The Honorable Diana DeGette
Ranking Member, Subcommittee on Health
Committee on Energy and Commerce
U.S. House of Representatives
Washington, DC 20515

Dear Chairman Griffith, Ranking Member DeGette, and Members of the Subcommittee:

The Healthcare Nutrition Council (HNC) appreciates the opportunity to submit this statement for the record and urges the Subcommittee to advance H.R.2172, the Preserving Patient Access to Home Infusion Act.

HNC is an association representing manufacturers¹ of enteral nutrition (EN) formulas and oral nutrition supplements (ONS), including those categorized as medical foods², which provide essential nutrition support for patients who are unable to meet their needs through a normal diet. Our mission is to improve patient outcomes by advancing nutrition policies and actions that raise awareness and optimize access for people who require or benefit from advanced and specialized nutrition.

Many Medicare beneficiaries who require specialized nutrition support transition from acute care to home with complex therapy regimens and some transition from home parenteral nutrition to home enteral nutrition. For beneficiaries who require parenteral nutrition, home-based care can support continuity of treatment and reduce avoidable time in higher-intensity settings—provided the clinical infrastructure is in place to manage therapy safely over time. That infrastructure includes ongoing clinical oversight, timely monitoring, coordination among healthcare professionals including prescribers and pharmacists, and responsive troubleshooting across the full course of therapy.

The Preserving Patient Access to Home Infusion Act helps align Medicare policy with how home infusion is delivered and supported in practice. By modernizing the home infusion benefit to better reflect the professional services required across infusion days, including services that may occur between visits or outside the home, the bill supports provider participation and strengthens beneficiary access when home infusion is clinically appropriate. The bill's expansion of coverage to include all IV anti-infective drugs also supports timely transitions home and can reduce unnecessary reliance on facility settings driven by logistics rather than clinical need.

HNC supports the Preserving Patient Access to Home Infusion Act because it advances a workable approach to home-based care for medically complex beneficiaries and helps protect continuity of treatment for patients who depend on specialized nutrition support.

We appreciate the Subcommittee's consideration and would welcome the opportunity to provide any additional information that is helpful.

¹ HNC members are Abbott Nutrition, Nestle Health Science, and Nutricia North America

² A medical food as defined in section 5(b)(3) of the Orphan Drug Act. 21 USC 360ee(b)(3): "a food which is formulated to be consumed or administered enterally under the supervision of a physician, and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."

If you have any questions, please contact Jordan Marshall MPH, Healthcare Nutrition Council, at jmarshall@healthcarenutrition.org or 202-591-2484.

Sincerely,

A handwritten signature in black ink that reads "Carla A. Saunders". The signature is written in a cursive style with a large initial 'C'.

Carla Saunders
Executive Director